bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell… Read more
bioAffinity Technologies, Inc. (BIAF) - Net Assets
Latest net assets as of September 2025: $8.90 Million USD
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has net assets worth $8.90 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.55 Million) and total liabilities ($2.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.90 Million |
| % of Total Assets | 77.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.81 |
bioAffinity Technologies, Inc. - Net Assets Trend (2019–2024)
This chart illustrates how bioAffinity Technologies, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for bioAffinity Technologies, Inc. (2019–2024)
The table below shows the annual net assets of bioAffinity Technologies, Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.60 Million | -46.41% |
| 2023-12-31 | $4.86 Million | -56.03% |
| 2022-12-31 | $11.04 Million | +169.94% |
| 2021-12-31 | $-15.79 Million | -4.76% |
| 2020-12-31 | $-15.07 Million | -273.50% |
| 2019-12-31 | $-4.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to bioAffinity Technologies, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3872610500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $106.59K | 4.10% |
| Other Components | $56.14 Million | 2157.53% |
| Total Equity | $2.60 Million | 100.00% |
bioAffinity Technologies, Inc. Competitors by Market Cap
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zuleika Gold Ltd
AU:ZAG
|
$5.09 Million |
|
Snail, Inc. Class A Common Stock
NASDAQ:SNAL
|
$5.09 Million |
|
Michael Anthony Holdings Inc
PINK:MAJJ
|
$5.09 Million |
|
Global Star Acquisition Inc.
NASDAQ:GLSTU
|
$5.09 Million |
|
Ulima Nitra PT
JK:UNIQ
|
$5.08 Million |
|
XPLUS SA ZY -01
F:75R
|
$5.08 Million |
|
BIOFISH HOLDING AS NK 1
F:9R2
|
$5.08 Million |
|
Sical Logistics Limited
NSE:SICALLOG
|
$5.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in bioAffinity Technologies, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,855,255 to 2,602,036, a change of -2,253,219 (-46.4%).
- Net loss of 9,040,000 reduced equity.
- New share issuances of 4,350,885 increased equity.
- Other factors increased equity by 2,435,896.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.04 Million | -347.42% |
| Share Issuances | $4.35 Million | +167.21% |
| Other Changes | $2.44 Million | +93.61% |
| Total Change | $- | -46.41% |
Book Value vs Market Value Analysis
This analysis compares bioAffinity Technologies, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.43x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-16.41 | $2.74 | x |
| 2020-12-31 | $-61.29 | $2.74 | x |
| 2021-12-31 | $-64.21 | $2.74 | x |
| 2022-12-31 | $73.64 | $2.74 | x |
| 2023-12-31 | $16.65 | $2.74 | x |
| 2024-12-31 | $6.44 | $2.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently bioAffinity Technologies, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -347.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -96.56%
- • Asset Turnover: 1.44x
- • Equity Multiplier: 2.50x
- Recent ROE (-347.42%) is below the historical average (-97.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.90 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.76 Million |
| 2021 | 0.00% | -484411.41% | 0.00x | 0.00x | $-4.75 Million |
| 2022 | -73.84% | -169771.25% | 0.00x | 1.10x | $-9.26 Million |
| 2023 | -163.47% | -313.47% | 0.31x | 1.69x | $-8.42 Million |
| 2024 | -347.42% | -96.56% | 1.44x | 2.50x | $-9.30 Million |
Industry Comparison
This section compares bioAffinity Technologies, Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,017,327,365
- Average return on equity (ROE) among peers: -24.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $8.90 Million | 0.00% | 0.30x | $5.08 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |